Fisher Asset Management LLC Purchases 132,906 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Fisher Asset Management LLC lifted its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 68.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 327,505 shares of the biopharmaceutical company’s stock after purchasing an additional 132,906 shares during the quarter. Fisher Asset Management LLC owned 0.20% of ACADIA Pharmaceuticals worth $6,010,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Quest Partners LLC lifted its position in ACADIA Pharmaceuticals by 42.3% in the 3rd quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 1,047 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of ACADIA Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,999 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 1,066 shares during the last quarter. KBC Group NV lifted its holdings in shares of ACADIA Pharmaceuticals by 67.0% in the fourth quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 2,044 shares in the last quarter. Atria Investments Inc boosted its position in shares of ACADIA Pharmaceuticals by 10.8% during the third quarter. Atria Investments Inc now owns 24,437 shares of the biopharmaceutical company’s stock valued at $376,000 after buying an additional 2,384 shares during the last quarter. Finally, Advisors Asset Management Inc. grew its holdings in ACADIA Pharmaceuticals by 13.4% during the third quarter. Advisors Asset Management Inc. now owns 21,087 shares of the biopharmaceutical company’s stock worth $324,000 after buying an additional 2,499 shares in the last quarter. 96.71% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ACAD. HC Wainwright reissued a “buy” rating and set a $27.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Needham & Company LLC reissued a “buy” rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Guggenheim lowered ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the company from $23.00 to $20.00 in a report on Friday, January 3rd. Deutsche Bank Aktiengesellschaft started coverage on ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They set a “hold” rating and a $22.00 price target for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Nine equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, ACADIA Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

ACADIA Pharmaceuticals Price Performance

Shares of ACAD stock opened at $18.26 on Wednesday. The stock’s fifty day moving average price is $18.44 and its 200 day moving average price is $16.88. ACADIA Pharmaceuticals Inc. has a 1-year low of $14.15 and a 1-year high of $24.27. The company has a market cap of $3.04 billion, a price-to-earnings ratio of 23.41 and a beta of 0.37.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.